Commercialization

Proven solutions for successful market launches of new medical products and services, successful integration of innovations in healthcare.

lazy picture

Contract research

"To obtain a regulatory approval and reach the market, a biotechnology development must successfully undergo preclinical and clinical trials (PCTs and CTs). The procedure for conducting these tests is strictly regulated, and the regulator evaluates the testing results thoroughly. Because of this, biotech companies normally conduct PCTs and CTs at accredited contract research organizations (CROs).

Artgen’s experience and expertise help create proper trial protocols, optimize their cost and timing, and increase the probability of successful completion of PCTs and CTs.

Our experience

Completed PCTs and CTs (fully or in part) for the following innovations:

  • Neovasculgen.
  • SPRS Therapy.
  • Histograft.
  • Betuvax.
  • Tetraflubet.
  • Coronapass assays.
  • Combined vaccine.
  • Prenetix.
  • Embryotest.

Contract manufacturing

Obtaining a marketing authorization (MA), conducting PCTs and CTs require a licensed high-tech site that meets strict GMP (good manufacturing practice) rules.

Organizing such a production facility is a long and costly process that requires a variety of highly qualified experts and competencies. It is extremely difficult for biotech startups to organize a production facility of this level on their own.

Artgen provides the necessary competencies for the development of industrial regulations, production of primary batches, creation of a set of production documents, and technology transfer.

Our experience

Organizing contract manufacturing:

  • Neovasculgen drug.
  • Histograft medical device (MD).
  • Betuvax vaccine.

Market access

Market access is the work that must be done for a registered drug to reach the market. It means that physicians will be able to prescribe the drug to patients in accordance with clinical guidelines, medical institutions will be able to purchase it in accordance with the lists (EDL) and medical standards (DRG, GVD), and insurance companies will be able to reimburse the costs of treatment using the drug.

Our experience

Neovasculgen is included in:

  • EDL (essential drug list).
  • DRG (diagnosis-related group).
  • GVD (global value dossier).
  • Clinical guidelines.

PR/GR/IR

The biotechnology market is an area with high entry barriers. Therefore, for a product to be implemented successfully, PR (public relations), GR (government relations), and IR (investor relations) must begin long before registration to gain support for the product even before it enters the market.

Our experience

Artgen’s experience and expertise allow us to build and maintain long-term and effective communications with physicians, patients, investors, representatives of regulators and development institutes, which contributes to the successful implementation and distribution of the ecosystem developments.

Investment management and fundraising

ЗCosts of biotech companies increase as their development gets closer to market, prompting the need for new fundraising rounds. Whatever the investment source, a venture capital fund, an IPO, or private placement, investors expect their investments to grow and regular reports on the company’s financial results and performance. This is why effective capital management competencies are just as important as the fundraising experience. The key function of investment management is to ensure the efficient use of investments and protect the capital interests.

Artgen’s ecosystem acts as an “investment bank”, providing a full range of specialized services for the group companies:


  • investment analysis and strategic planning,
  • determination and monitoring of return on capital targets, analysis of the use efficiency of attracted investments,
  • assessment and management of the member companies’ investment attractiveness,
  • planning of and support for new rounds of investments,
  • providing access to public capital markets.

Our experience

Investor returns since the IPO:

  • Artgen — 11х
  • Gemabank — 2х
  • Genetico — 2х

Credit rating from ACRA agency:

  • Artgen — BB+
  • MMCB — ВВ+

Successfully fulfilled commitments to investors:

  • RVK — RUB 175 million
  • RP — RUB 300 million
  • FRVI — RUB 66 million

Medical marketing

Medical marketing means actions aimed at promoting, implementing in medical practice, and increasing sales of medical services, products, or technologies.

It uses a number of tools:


  • organizing interaction with opinion leaders in medical fields,
  • speaking at medical conferences,
  • conducting post-market CTs,
  • conducting CTs to expand the development’s indications for use,
  • creating joint programs with schools of continuing medical education (CME),
  • conducting workshops,
  • support for publication of the results of using the development.

Our experience

  • Therapeutic angiogenesis (Neovasculgen).
  • Gene-activated matrices for bone grafting (Histograft).
  • Autologous fibroblasts for the correcting skin damage (SPRS Therapy).
  • Embryo PGT for the treatment of infertility and IVF (Embryotest).
  • NIPT screening during pregnancy (Prenetix).
  • Genome and exome genetic research.
  • Isolation and storage of umbilical cord blood HSCs.